To clarify whether rL-RVG modulates the MEK/ERK signaling pathway to suppress cell migration, corynoxenine, an inhibitor of the MEK/ERK pathway, was used to pre-treat gastric cancer cells (Fig. 6a-d). The gene discussed is MAP2K7; the disease is gastric cancer.